Skip to main content
. 2020 Sep 11;10(9):629. doi: 10.3390/brainsci10090629

Table 5.

Adolescents/adults with FXS in placebo-treated failed clinical trials: outcome measures improved.

Endpoint Correlation of Studies Heterogeneity (I2) Heterogeneity
p-Value
Meta-Analysis Type Mean Score Change 95%CI Change
p-Value
% Improvement
Lower Upper
Caregiver Rated ND
Vineland-II Comp 0.7 4 0.00 0.44 Fixed 1.74 0.08 3.39 0.040 ND
Vineland-II Comp * 0.5 4 0.00 0.44 Fixed 1.74 0.08 3.39 0.040 ND
ABC-CFX Total 0.7 2 0.00 0.72 Fixed −8.60 −12.45 −4.76 <0.001 ND
ABC-CFX Total * 0.5 2 0.00 0.72 Fixed −8.60 −12.45 −4.76 <0.001 ND
ABC-CFX Hyper 0.7 2 0.00 0.84 Fixed −1.37 −2.26 −0.49 0.002 ND
ABC-CFX Hyper * 0.5 2 0.00 0.84 Fixed −1.37 −2.26 −0.49 0.002 ND
ABC-CFX SA 0.7 3 0.79 0.01 Random −1.65 −2.61 −0.68 0.001 ND
ABC-CFX SA * 0.5 3 0.79 0.01 Random −1.65 −2.61 −0.68 0.001 ND
ABC-CFX Stereo 0.7 2 0.00 0.69 Fixed −1.04 −1.58 −0.50 <0.001 ND
ABC-CFX Stereo * 0.5 2 0.00 0.69 Fixed −1.04 −1.58 −0.50 <0.001 ND

Abbreviations: FXS, fragile X syndrome; Vineland-II Comp, Vineland Adaptive Behavior Scale-2nd edition, Composite; ABC-CFX Hyper, Aberrant Behavior Checklist-Community Hyperactivity refactored for FXS; ABC-CFX Stereo, Stereotypy; ABC-CFX SA, Social Avoidance; ABC-CFX Total, Total Score; ND, no data. * Meta-analysis conducted using a pre-post correlation of 0.0 has almost identical values.